Issue 98, 2019

Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-XL

Abstract

BCL-XL, an anti-apoptotic BCL-2 family protein, plays a key role in cancer cell survival. However, the potential of BCL-XL as an anti-cancer target has been hampered by the on-target platelet toxicity because platelets depend on BCL-XL to maintain their viability. Here we report the development of a PROTAC BCL-XL degrader, XZ424, which has increased selectivity for BCL-XL-dependent MOLT-4 cells over human platelets compared with conventional BCL-XL inhibitors. This proof-of-concept study demonstrates the potential of utilizing a PROTAC approach to achieve tissue selectivity.

Graphical abstract: Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-XL

Supplementary files

Article information

Article type
Communication
Submitted
14 Sep 2019
Accepted
12 Nov 2019
First published
19 Nov 2019

Chem. Commun., 2019,55, 14765-14768

Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-XL

X. Zhang, D. Thummuri, Y. He, X. Liu, P. Zhang, D. Zhou and G. Zheng, Chem. Commun., 2019, 55, 14765 DOI: 10.1039/C9CC07217A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements